Page 1 10:53 <golam shameem> 06/15/2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1626gms

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS	21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	23	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	24	May 27	Explore APOLLIT with free connect time in June 2004

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

10677451

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:43:34 ON 15 JUN 2004

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:43:54 ON 15 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4
DICTIONARY FILE UPDATES: 14 JUN 2004 HIGHEST RN 693217-50-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10677451.str



10677451

chain nodes :
6 13 14 15
ring nodes :
1 2 3 4 5 7 8 9 10 11 12
chain bonds :
1-6 3-13 5-10 7-15 13-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-5 1-6 4-5 5-10 7-15 13-14
exact bonds :
1-2 2-3 3-4 3-13
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:44:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 446 TO ITERATE

100.0% PROCESSED 446 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7653 TO 10187
PROJECTED ANSWERS: 3403 TO 5157

L2 50 SEA SSS SAM L1

```
=> s l1 sss full
FULL SEARCH INITIATED 10:44:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   9450 TO ITERATE

100.0% PROCESSED    9450 ITERATIONS                    4490 ANSWERS
SEARCH TIME: 00.00.01

L3          4490 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10677451a.str
```




```
chain nodes :
6  13  14
ring nodes :
1  2  3  4  5  7  8  9  10  11  12  16  17  18  19  20  21
chain bonds :
1-6  3-13  5-10  7-16  13-14
ring bonds :
1-2  1-5  2-3  3-4  4-5  7-8  7-12  8-9  9-10  10-11  11-12  16-17  16-20  17-18
18-19  18-21  19-20  19-21
exact/norm bonds :
1-2  1-5  1-6  2-3  3-4  3-13  4-5  5-10  7-16  13-14  16-17  16-20  17-18  18-19
18-21  19-20  19-21
normalized bonds :
7-8  7-12  8-9  9-10  10-11  11-12
isolated ring systems :
containing 1 : 7 : 16 :


G1:O,S,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:CLASS  14:CLASS  16:CLASS  17:Atom  18:Atom  19:Atom  20:Atom
21:Atom



L4       STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4                STR
```



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 10:48:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 10:48:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      7 TO ITERATE

100.0% PROCESSED       7 ITERATIONS                          6 ANSWERS
SEARCH TIME: 00.00.01

L6            6 SEA SSS FUL L4

=> FIL CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               313.36     313.57

FILE 'CAPLUS' ENTERED AT 10:48:54 ON 15 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 15 Jun 2004 VOL 140 ISS 25
FILE LAST UPDATED: 14 Jun 2004 (20040614/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6
L7 1 L6

=> d l7 ibib abs hitstr tot

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:333714 CAPLUS
DOCUMENT NUMBER: 140:357327
TITLE: Preparation of bicyclic[3.1.0]oxazolidinones and related compounds as antibacterial agents
INVENTOR(S): Gordeev, Mikhail Fedor; Renslo, Adam; Patel, Dinesh Vinoobhai
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033451	A1	20040422	WO 2003-US28560	20031003

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-417735P P 20021009
OTHER SOURCE(S): MARPAT 140:357327
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R2, R3 = H, F; R4, R5 = H, Cl, F, etc.; R6, R7 = H, F, OH, etc.; R8 = H, F, OH, etc.; A = 5-methyl-2-oxazolidinonyl, 4,5-dihydro-5-Me-oxazolyl, dihydro-5-Me-2(3H)-furanonyl, etc.; B = (CH2)n; n = 0-1; X = N, CH; Y = N, O, S; Z = NHCOR1, NHCSR1, CONHR1, etc.; R1 = H, NH2, NH-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of CBZ-protected benzenamine II, e.g., prepared from benzyl 3-pyrroline-1-carboxylate in 5-steps, and (S)-acetic acid 2-acetylamino-1-chloromethylethyl ester afforded oxazolidinone III in 62% yield. In S. aureus Min. Inhibitory

Concentration (MIC) growth studies, 6-examples of compds. I exhibited MIC values ranging from 1-8 μg/mL, i.e., the MIC value of oxazolidinone III was 1 μg/mL. Compds. I are claimed useful for the treatment of skin and eye infections.

IT **681424-68-0P 681424-79-3P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681424-68-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-(6-oxa-3-azabicyclo[3.1.0]hex-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681424-79-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(3,6-diazabicyclo[3.1.0]hex-3-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **681424-69-1P 681424-80-6P 681424-81-7P 681424-82-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681424-69-1 CAPLUS
CN Propanamide, N-[[(5S)-3-[3,5-difluoro-4-(6-oxa-3-azabicyclo[3.1.0]hex-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681424-80-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(6-acetyl-3,6-diazabicyclo[3.1.0]hex-3-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681424-81-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[6-(methoxyacetyl)-3,6-diazabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681424-82-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[6-[(acetyloxy)acetyl]-3,6-diazabicyclo[3.1.0]hex-3-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 10:43:34 ON 15 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 10:43:54 ON 15 JUN 2004
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            4490 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5              0 S L4
L6              6 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:48:54 ON 15 JUN 2004
L7              1 S L6

=> s l3
L8            677 L3

=> s l8 and thu
            138 THU
        2161015 THUS
        2161138 THU
                  (THU OR THUS)
L9             99 L8 AND THU

=> s l9 and p/dt
        4368212 P/DT
L10            74 L9 AND P/DT

=> s l10 and py<=2002
       22503304 PY<=2002
L11            58 L10 AND PY<=2002

=> s l11 and us/pc
        1283768 US/PC
L12            42 L11 AND US/PC

=> d l12 ibib abs hitstr 1-15

L12  ANSWER 1 OF 42  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2003:492705  CAPLUS
DOCUMENT NUMBER:          139:69253
TITLE:                    Preparation of phenyl oxazolidinone derivatives as
                          potential antimicrobials
```

INVENTOR(S): Mehta, Anita; Arora, Sudershan K.; Das, Biswajit; Ray, Abhijit; Rudra, Sonali; Rattan, Ashok
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 906,215.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119817	A1	20030626	US 2002-51784	20020117 <--
US 2002103186	A1	20020801	US 2001-906215	20010716 <--
US 6734307	B2	20040511		

PRIORITY APPLN. INFO.: US 2001-906215 A2 20010716
IN 2000-DE654 A 20000717
OTHER SOURCE(S): CASREACT 139:69253; MARPAT 139:69253
GI



I



II

AB Substituted Ph oxazolidinones, e.g. of formula I [T = heterocyclic ring, aryl; R = alkyl, halo, CN, CHO, NH2, NO2, etc.; X = CH, CH-S, CH-O, N; Y, Z = H, alkyl, cycloalkyl, bridging group; U, V = alkyl, F, CL, Br, etc.; W = CH2, CO, CH2NH, etc.; R1 = NHCHR2, NR2CSR2; R2 = H, alkyl, cycloalkyl, alkoxy, etc.], are prepared This invention also relates to pharmaceutical compns. containing the compds. of the present invention as antimicrobials. The compds. are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp. **Thus**, II was prepared and showed antibacterial activity against several strains.

IT **392659-38-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of Ph oxazolidinone derivs. as antibacterial agents)

RN 392659-38-0 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **392659-23-3P 392659-24-4P 392659-25-5P**
392659-26-6P 392659-27-7P 392659-28-8P
392659-29-9P 392659-30-2P 392659-31-3P
392659-32-4P 392659-33-5P 392659-34-6P
392659-36-8P 392659-37-9P 392659-41-5P
392659-42-6P 392659-43-7P 392659-44-8P
392659-45-9P 392659-46-0P 392659-47-1P
392659-48-2P 392659-49-3P 392659-50-6P
392659-51-7P 392659-52-8P 392659-55-1P
392659-56-2P 392659-57-3P 392659-58-4P
392659-59-5P 392659-60-8P 392659-61-9P
392659-62-0P 392659-63-1P 392659-64-2P
392659-65-3P 392659-66-4P 392659-67-5P
392659-68-6P 392659-69-7P 392659-70-0P
392659-71-1P 392659-73-3P 392659-74-4P
392659-75-5P 392659-76-6P 392659-77-7P
392659-80-2P 392659-81-3P 392659-86-8P
392659-87-9P 392659-88-0P 392659-90-4P
392659-92-6P 392659-93-7P 392659-94-8P
392659-95-9P 392660-87-6P 548762-60-3P
548762-62-5P 548762-68-1P 548762-69-2P
548762-70-5P 548762-71-6P 548762-72-7P
548762-73-8P 548762-74-9P 548762-75-0P
548762-76-1P 548762-78-3P 548762-79-4P
548762-80-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph oxazolidinone derivs. as antibacterial agents)

RN 392659-23-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(2-furanylcarbonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-24-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-formyl-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-25-5 CAPLUS
CN 2-Furancarboxylic acid, 5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-26-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[(5-bromo-2-furanyl)carbonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-27-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[[5-(chloromethyl)-2-furanyl]carbonyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-28-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)carbonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-29-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(oxo-2-thienylacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-30-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(3-furanylcarbonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-31-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-32-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-33-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(2-furanylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-34-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(2-thienylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-36-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(2-thienylacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-37-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[(4-bromo-2-thienyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-41-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(1H-pyrrol-2-ylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-42-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(3-methyl-2-thienyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-43-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(3-furanylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-44-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-methyl-2-thienyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-45-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-46-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-thienyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-47-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[[5-(4-thiomorpholinylmethyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-48-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[[5-(4-morpholinylmethyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-49-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[[5-[(acetyloxy)methyl]-2-furanyl]methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-50-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-51-7 CAPLUS
CN Acetamide, 2,2-dichloro-N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-52-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-thienyl)carbonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 392659-55-1 CAPLUS
CN 3-Furancarboxamide, N-[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-56-2 CAPLUS
CN 2-Furancarboxamide, N-[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-5-bromo-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-57-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1α,5α,6α)-6-[methyl[(5-nitro-2-thienyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-58-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1α,5α,6α)-6-[methyl[(5-nitro-2-furanyl)methyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-59-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1α,5α,6α)-6-[[[(5-formyl-2-furanyl)methyl]methylamino]methyl]-3-azabicyclo[3.1.0]hex-3-

yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-60-8 CAPLUS
CN 2-Furancarboxylic acid, 5-[[[[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methylamino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-61-9 CAPLUS
CN 2-Thiopheneacetamide, N-[[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-62-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1α,5α,6α)-6-[[methyl[(5-nitro-2-thienyl)methyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-63-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1α,5α,6α)-6-[[methyl[(5-nitro-2-furanyl)methyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-64-2 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[[(5-formyl-2-furanyl)methyl]methylamino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-65-3 CAPLUS
CN Benzamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-3,5-difluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-66-4 CAPLUS
CN 2-Furancarboxamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-5-bromo-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-67-5 CAPLUS
CN 2-Furancarboxamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-N-methyl-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-68-6 CAPLUS
CN 3-Furancarboxamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-69-7 CAPLUS

CN 2-Furancarboxamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-70-0 CAPLUS
CN 2-Thiopheneacetamide, N-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-71-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(2-furanylmethyl)methylamino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-73-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[methyl[(5-nitro-2-furanyl)methyl]amino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-74-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[methyl[(5-nitro-2-thienyl)methyl]amino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-75-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[methyl(2-thienylmethyl)amino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-76-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[methyl[(5-methyl-2-thienyl)methyl]amino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-77-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[[(5-bromo-2-thienyl)methyl]methylamino]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-80-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[hexahydro-4-[(5-nitro-2-thienyl)methyl]-1H-1,4-diazepin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-81-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(3-furanylmethyl)hexahydro-1H-1,4-diazepin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-86-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[(5-cyano-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-87-9 CAPLUS
CN 2-Furancarboxylic acid, 5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-88-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[4-[[5-(1,3-dioxan-2-yl)-2-furanyl]methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-90-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[[5-(4-morpholinylcarbonyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-92-6 CAPLUS
CN 2-Thiopheneacetamide, N-[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-93-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1α,5α,6α)-6-[[(5-formyl-2-furanyl)methyl]methylamino]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-94-8 CAPLUS
CN 3-Thiophenecarboxamide, N-[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-95-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[[5-(fluoromethyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-87-6 CAPLUS
CN 2-Furancarboxamide, N-[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]-N-methyl-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 548762-60-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 548762-62-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 392659-38-0
CMF C21 H24 F N5 O6

Absolute stereochemistry.



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 548762-68-1 CAPLUS
CN Acetamide, 2,2-dichloro-N-[[(5S)-3-[3-fluoro-4-[4-(hydroxydiphenylacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 548762-69-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(3-furanylmethyl)methylamino]-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 548762-70-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(5-formyl-2-furanyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 548762-71-6 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[hexahydro-4-(2-thienylacetyl)-1H-1,4-diazepin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 548762-72-7 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-[4-[[5-(difluoromethyl)-2-furanyl]methyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 548762-73-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[[5-[(hydroxyimino)methyl]-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 548762-74-9 CAPLUS
CN Benzeneacetic acid, 4-[[[[[[5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]-2-furanyl]methylene]amino]oxy]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 548762-75-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[[5-(hydrazonomethyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 548762-76-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[[5-(hydroxymethyl)-2-furanyl]methyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 548762-78-3 CAPLUS
CN 2-Furancarboxamide, 5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 548762-79-4 CAPLUS

CN Carbamic acid, [1-[[5-[[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]methyl]-2-furanyl]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 548762-80-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-[(2Z)-2-furanyl(methoxyimino)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **154590-66-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of Ph oxazolidinone derivs. as antibacterial agents)
RN 154590-66-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **172966-99-3P 392659-54-0P 392660-04-7P**
392660-05-8P 392660-06-9P 392660-14-9P
392660-15-0P 392660-16-1P 392660-17-2P
392660-24-1P 392660-25-2P 392660-26-3P
392660-32-1P 392660-33-2P 392660-34-3P
392660-35-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of Ph oxazolidinone derivs. as antibacterial agents)

RN 172966-99-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(methylamino)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392659-54-0 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1α,5α,6α)-6-(methylamino)-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-

oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-04-7 CAPLUS
CN Carbamic acid, [(1α,5α,6α)-3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-05-8 CAPLUS
CN Carbamic acid, [(1α,5α,6α)-3-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-06-9 CAPLUS
CN Carbamic acid, [(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-14-9 CAPLUS
CN Carbamic acid, [[(1α,5α,6α)-3-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-15-0 CAPLUS
CN Carbamic acid, [[(1α,5α,6α)-3-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-16-1 CAPLUS
CN Carbamic acid, [[(1α,5α,6α)-3-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-azabicyclo[3.1.0]hex-6-yl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-17-2 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[(1α,5α,6α)-6-[(methylamino)methyl]-3-azabicyclo[3.1.0]hex-3-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-24-1 CAPLUS
CN Carbamic acid, [1-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-

fluorophenyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-25-2 CAPLUS
CN Carbamic acid, [1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-26-3 CAPLUS
CN Carbamic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-32-1 CAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-33-2 CAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-34-3 CAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 392660-35-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(hexahydro-1H-1,4-diazepin-1-yl)phenyl]-

2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:356028 CAPLUS
DOCUMENT NUMBER: 138:350275
TITLE: Crystal structures of ribosome 50S subunit and its complexes with protein synthesis inhibitors and use for homology modeling and rational antibiotic design
INVENTOR(S): Steitz, Thomas A.; Moore, Peter B.; Ban, Nenad; Nissen, Poul; Hansen, Jeffrey; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; Ippolito, Joseph A.
PATENT ASSIGNEE(S): Yale University, USA; Rib-X Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 215 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1308457	A1	20030507	EP 2002-255442	20020802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2002086308	A1	20020704	US 2001-922251	20010803 <--
EP 1188769	A2	20020320	EP 2001-306825	20010809 <--
EP 1188769	A3	20020710		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2003153002	A1	20030814	US 2002-72634	20020208 <--

PRIORITY APPLN. INFO.:

US 2001-922251	A	20010803
EP 2001-306825	A	20010809
US 2002-348731P	P	20020114
US 2002-352024P	P	20020125
US 2002-72634	A	20020208
US 2000-223977P	P	20000809
US 2000-635708	A2	20000809

US 2001-306996P P 20010720
US 2001-309281P P 20010801

AB The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The three-dimensional structure of the large 50S ribosomal subunit from Haloarcula marismortui is completely refined at 2.4 Å resolution The model includes 2876 RNA nucleotides, 2701 amino acids from 28 ribosomal proteins, 117 magnesium ions, 88 monovalent cations, and 7898 water mols. In addition, x-ray diffraction data is used to solve the structure of the large ribosome subunit complexed with each of the following antibiotics: anisomycin, blasticidin, carbomycin A, tylosin, sparsomycin, virginiamycin M. spiramycin, azithromycin, linezolid, or erythromycin. **Thus**, the invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. The methods and compns. of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism. Syntheses are described for production of hybrid antibiotics between sparsomycin and chloramphenicol (two forms of sparsochloramphenicol) and between sparsomycin and anisomycin (sparsoanisomycin).

IT **165800-03-3D**, Linezolid, complexes with ribosomal 50S subunit
RL: PRP (Properties)
(crystal structures of ribosome 50S subunit and its complexes with protein synthesis inhibitors and use for homol. modeling and rational antibiotic design)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:736895 CAPLUS
DOCUMENT NUMBER: 137:247686
TITLE: Preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections

INVENTOR(S): Hester, Jackson B.
PATENT ASSIGNEE(S): Pharmacia and Upjohn Co., USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 778,603, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137754	A1	20020926	US 2002-42916	20020109 <--
US 6642238	B2	20031104		
US 2001047004	A1	20011129	US 2001-778603	20010207 <--

PRIORITY APPLN. INFO.: US 2000-181640P P 20000210
US 2001-778603 B2 20010207

OTHER SOURCE(S): MARPAT 137:247686
GI



I



II



III

AB Oxazolidinone thioamides, such as I [R1 = H, NH2, alkylamino, alkenyl, alkyloxy, alkylthio, cycloalkyl, alkyl; R2, R3 = H, F, Cl, alkyl; R4 = CN, acyl, thioacyl, alkyloxyacyl, sulfonylmethylacyl, etc.] which have potent activities against gram-pos. and gram-neg. bacteria, were prepared for therapeutic use in the treatment of bacterial infections particularly of the skin and eye. **Thus**, PNU 255889 (II) was prepared via a multistep synthetic sequence which included N-acylation of III with MeSCH2CO2H, S-oxidation with sodium periodate, conversion of the phthalimido group to NH2 and N-thioacylation with MeCH2CS2Me. The prepared oxazolidinone thioamides were evaluated for min. inhibitory concns. of antibacterial activity against bacterial strains such as Staphylococcus aureus, S. epidermidis, Streptococcus pneumoniae, Enterococcus faecalis

Moraxella catarrhalis and H. influenzae. Pharmaceutical formulations for oral, topical, transdermal, and parenteral delivery were discussed.

IT **345224-19-3P 354578-48-6P 354578-49-7P**
354578-50-0P 354578-51-1P 354578-52-2P
354578-53-3P 354578-54-4P 354578-55-5P
354578-56-6P 354578-61-3P 354578-62-4P
354578-65-7P 354578-66-8P 354578-67-9P
354578-68-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections)

RN 345224-19-3 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-48-6 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(methylsulfinyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-49-7 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(methylthio)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-50-0 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(methylthio)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-51-1 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(methylsulfonyl)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-52-2 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(methylsulfonyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-53-3 CAPLUS
CN Carbamic acid, [[(5S)-3-[4-(4-cyano-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-54-4 CAPLUS
CN 1-Piperazinecarbonitrile, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 354578-55-5 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[[[(methylamino)carbonyl]oxy]acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354578-56-6 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[[[(methylamino)carbonyl]oxy]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-61-3 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354578-62-4 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-65-7 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[1-oxo-3-(phenylmethoxy)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-66-8 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-(3-hydroxy-1-oxopropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-67-9 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-(phenoxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-68-0 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-(phenoxyacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **354578-63-5P 354578-64-6P 354819-74-2P**
354819-77-5P 354819-82-2P 354819-83-3P
354819-85-5P 354819-86-6P 354819-87-7P
354819-94-6P 354819-96-8P 354820-02-3P
354820-03-4P 354820-05-6P 354820-07-8P
354987-17-0P 354987-18-1P 354987-21-6P
354987-23-8P 354987-24-9P 354987-25-0P
354987-26-1P 354987-30-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections)

RN 354578-63-5 CAPLUS

CN Propanethioamide, N-[[(5S)-3-[4-[4-(1,3-dioxobutyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354578-64-6 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[1-oxo-3-(phenylmethoxy)propyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354819-74-2 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(methylsulfinyl)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354819-77-5 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(methylthio)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354819-82-2 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(methylsulfonyl)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354819-83-3 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(1-thioxoethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354819-85-5 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(4-cyano-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354819-86-6 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[[[(methylamino)carbonyl]oxy]acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354819-87-7 CAPLUS
CN Carbonic acid, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354819-94-6 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(2S)-2-hydroxy-3-methoxy-1-oxopropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354819-96-8 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-[4-[(2S)-2,3-dimethoxy-1-oxopropyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354820-02-3 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(2S)-3-hydroxy-2-methoxy-1-oxopropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354820-03-4 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-[4-(1,2-dioxopropyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354820-05-6 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(3-hydroxy-1-oxopropyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354820-07-8 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(1-hydroxycyclopropyl)carbonyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

S

RN 354987-17-0 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(phenoxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354987-18-1 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354987-21-6 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-[4-[(2R)-2,3-dihydroxy-1-oxopropyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354987-23-8 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[3-hydroxy-2-(hydroxymethyl)-2-methyl-1-oxopropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354987-24-9 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(2S)-2-hydroxy-1-oxo-3-phenylpropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354987-25-0 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(2R)-2-hydroxy-1-oxo-3-phenylpropyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

S

RN 354987-26-1 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-[(2R)-hydroxyphenylacetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 354987-30-7 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-[4-[(2S)-(acetyloxy)phenylacetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

IT **273376-76-4 273376-91-3 273376-95-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections)

RN 273376-76-4 CAPLUS

CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-91-3 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-95-7 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **345224-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections)
RN 345224-18-2 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:637662 CAPLUS
DOCUMENT NUMBER: 137:185482
TITLE: Preparation of isoquinolinylphenyloxazolidinone antibacterials
INVENTOR(S): Paget, Steven D.; Weidner-Wells, Michele A.; Werblood, Harvey M.
PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064574	A2	20020822	WO 2002-US3982	20020206 <--
WO 2002064574	A3	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003176422	A1	20030918	US 2002-72534	20020206 <--
EP 1358185	A2	20031105	EP 2002-726571	20020206

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-266938P P 20010207
WO 2002-US3982 W 20020206
OTHER SOURCE(S): MARPAT 137:185482
GI



AB Oxazolidinones I [R = OH, N3, OCH2Ph, acyloxy, aryloxy, heteroaryloxy, O3SR2, (un)substituted NH2; R1 = substituted Ph; R2 = Ph, tolyl, alkyl] were prepared for use as antibacterial agents, particularly against antibiotic-resistant gram pos. organisms. **Thus**, 1,2,3,4-tetrahydroisoquinoline was N-substituted with 3,4-F2C6H3NO2, reduced to the amine, N-benzyloxycarbonylated, and treated with (R)-glycidyl butyrate to give the alc. II [R = OH] which was mesylated, treated with K phthalimide, hydrolyzed, and N-acetylated to give II [R = NHAc]. II [R = NHAc] had min. inhibitory concns. of Staphylococcus aureus OC4172 8, S. aureus OC2878 4, and Enterococcus faecium OC3312 8 μg/mL.

IT **449175-15-9P 449175-16-0P 449175-17-1P**
449175-18-2P 449175-19-3P 449175-20-6P
449175-21-7P 449175-22-8P 449175-23-9P

449175-24-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoquinolinylphenyloxazolidinone antibacterials)
RN 449175-15-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(3,4-dihydro-2(1H)-isoquinolinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-16-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-17-1 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(3,4-dihydro-1-oxo-2,6-naphthyridin-2(1H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-18-2 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-19-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(7,8-dihydro-2-methylpyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-20-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[7,8-dihydro-2-(2-methyl-4-thiazolyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-21-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-[7,8-dihydro-2-(4-pyridinyl)pyrido[4,3-

d]pyrimidin-6(5H)-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-22-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(7,8-dihydro-2-pyrazinylpyrido[4,3-d]pyrimidin-6(5H)-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-23-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-24-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1,4,6,7-tetrahydro-1-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **172966-53-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoquinolinylphenyloxazolidinone antibacterials)
RN 172966-53-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-oxo-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **449175-29-5P 449175-38-6P 449175-39-7P**
449175-40-0P 449175-49-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoquinolinylphenyloxazolidinone antibacterials)
RN 449175-29-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(3,4-dihydro-2(1H)-isoquinolinyl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-38-6 CAPLUS
CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-39-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-5-[[(triphenylphosphoranylidene)amino]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-40-0 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449175-49-9 CAPLUS
CN 2,6-Naphthyridin-1(2H)-one, 2-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:575074 CAPLUS
DOCUMENT NUMBER: 137:125148
TITLE: Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
INVENTOR(S): Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059116	A2	20020801	WO 2001-US44731	20011129 <--
WO 2002059116	A3	20021205		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20030013737 A1 20030116 US 2001-996927 20011129 <--
US 6689769 B2 20040210
EP 1349853 A2 20031008 EP 2001-994117 20011129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2000-257904P P 20001221
WO 2001-US44731 W 20011129
OTHER SOURCE(S): MARPAT 137:125148
GI



I



II

AB Substituted quinolones I [Y1 = CH, N; Y2, Y3 = C, N; R1 = H, alkyl, cycloalkyl, haloalkyl, halophenyl, LXmQ; R2 = H, alkyl, alkoxy, halo, haloalkoxy; R1R2 = atoms required to complete an (un)substituted 5-6-membered heterocyclic or heteroarom. ring; R3 = H, F; R4 = H, Me, NH2, F; R5 = H, LXmQ; L = bond, (un)substituted NH, NH(CH2)nNH; X = (un)substituted p-C6H4, 2,5-pyridinediyl; Q = Q1, Q2, Q3; m = 0, 1; n = 0-3; R6 = OH, alkoxy, aryloxy, acylamino] were prepared The quinolone derivs. possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases. **Thus**, the quinolone II was prepared from the 7-chloroquinolone and the piperazine fragments. II had min. inhibitory concs. against E. faecalis 0.25, S. aureus 0.5, S. pneumoniae 0.125, H. influenzae 8, M. catarrhalis 1, and E. coli 16 μg/mL.

IT **444335-12-0P 444335-14-2P 444335-22-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antimicrobial quinolone derivs. and their use to treat bacterial infections)

RN 444335-12-0 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-14-2 CAPLUS
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-[4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-9-fluoro-2,3-dihydro-3-methyl-7-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-22-2 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **444335-13-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of antimicrobial quinolone derivs. and their use to treat bacterial infections)
RN 444335-13-1 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **444335-20-0P 444335-21-1P 444335-23-3P**
444335-26-6P 444335-40-4P 444335-41-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antimicrobial quinolone derivs. and their use to treat bacterial infections)
RN 444335-20-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-21-1 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-23-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-26-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 444335-25-5
CMF C25 H23 F2 N3 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 444335-40-4 CAPLUS

CN Acetamide, N-[[(5S)-3-[4-(3-acetyl-6,7-difluoro-4-oxo-1(4H)-quinolinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-41-5 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **444335-24-4P 444335-42-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antimicrobial quinolone derivs. and their use to treat bacterial infections)
RN 444335-24-4 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444335-42-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:71873 CAPLUS
DOCUMENT NUMBER: 136:123671
TITLE: Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
INVENTOR(S): Kararli, Tugrul T.; Bandyopadhyay, Rebanta; Singh, Satish K.; Hawley, Leslie C.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002005815	A1	20020124	WO 2001-US22061	20010712	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2002035264	A1	20020321	US 2001-904098	20010712	<--
EP 1303271	A1	20030423	EP 2001-953462	20010712	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					

PRIORITY APPLN. INFO.:
US 2000-218101P P 20000713
US 2001-279285P P 20010328
US 2001-294838P P 20010531
US 2001-296388P P 20010606
WO 2001-US22061 W 20010712

OTHER SOURCE(S): MARPAT 136:123671

AB A pharmaceutical composition suitable for topical administration to an eye contains a selective COX-2 inhibitor or nanoparticles of a drug of low water solubility, at a concentration effective for the treatment and/or prophylaxis of a disorder in the eye, and 1 or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the composition has an effective residence time of 2-24 h. Also provided is a method of treating and/or preventing a disorder in an eye, the method comprising administering to the eye a composition of the invention. **Thus**, an ophthalmic nanoparticle suspension contained valdecoxib at 2.15 mg/g, 1.2% glycerin, 0.8% EDTA disodium salt, 4.0% Gelcarin GP-379NF, 0.21% SeaSpen PF and 0.82% Povidone.

IT **165800-03-3**, Linezolid **165800-04-4**, Eperezolid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic formulation of cyclooxygenase-2 inhibitor pharmaceuticals)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 165800-04-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:935600 CAPLUS
DOCUMENT NUMBER: 136:69815
TITLE: Preparation and formulation of N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide as a gram positive bactericide
INVENTOR(S): Barbachyn, Michael R.; Zurenko, Gary E.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098297	A2	20011227	WO 2001-US14854	20010614 <--
WO 2001098297	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2001011520	A	20030318	BR 2001-11520	20010614
EP 1294717	A2	20030326	EP 2001-944126	20010614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501150	T2	20040115	JP 2002-504253	20010614
US 20021560?2	A1	20021024	US 2001-881189	20010615 <--
US 6605609	B2	20030812		

PRIORITY APPLN. INFO.:
US 2000-212474P P 20000616
US 2000-236595P P 20000929
US 2001-285587P P 20010420
WO 2001-US14854 W 20010614

AB The title compound (I) was prepared **Thus**, benzyl 3,5-difluoro-4-(4-thiomorpholinyl)phenylcarbamate (preparation given) was cyclocondensed with (S)-N-(2-acetyloxy-3-chloropropyl)acetamide and the product oxidized to give I. Data for biol. activity of I were given.

IT **383199-88-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide as a gram pos. bactericide)

RN 383199-88-0 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **383199-87-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and formulation of N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide as a gram pos. bactericide)
RN 383199-87-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:798038 CAPLUS
DOCUMENT NUMBER: 135:339263
TITLE: Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
INVENTOR(S): Mesfin, Gebre-Mariam; Jensen, Richard K.
PATENT ASSIGNEE(S): Pharmacia + Upjohn Company, USA

SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001080841	A2	20011101	WO 2001-US10805	20010417	<--
WO 2001080841	A3	20020404			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2002010341	A1	20020124	US 2001-836804	20010417	<--
EP 1274426	A2	20030115	EP 2001-926589	20010417	
EP 1274426	B1	20040414			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003531167	T2	20031021	JP 2001-577940	20010417	
AT 264101	E	20040415	AT 2001-926589	20010417	

PRIORITY APPLN. INFO.: US 2000-198688P P 20000420
WO 2001-US10805 W 20010417

OTHER SOURCE(S): MARPAT 135:339263

AB The use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis is provided. **Thus**, (S)-N-[[3-[3-fluoro-4-(4-thiomorphonilyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide, S-oxide (I) was prepared by the reaction of (S)-N-[[3-[3-fluoro-4-(4-thiomorphonilyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiamine S-oxide with Et dithioacetate. I at a dose of 120 and 200 mg/kg/day orally caused an increase in bone mass and d. of trabecular bone of the sternum, femur/tibia, vertebrae, and basal cranium of rats.

IT **216868-70-1P 216868-86-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of thioamide oxazolidinones for treatment of bone resorption and osteoporosis)

RN 216868-70-1 CAPLUS

CN Thiourea, [[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-86-9 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **216869-13-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(use of thioamide oxazolidinones for treatment of bone resorption and osteoporosis)
RN 216869-13-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **216869-14-6P 216869-39-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(use of thioamide oxazolidinones for treatment of bone resorption and osteoporosis)
RN 216869-14-6 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-39-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:545487 CAPLUS
DOCUMENT NUMBER: 135:112030
TITLE: Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
INVENTOR(S): Percel, Phillip J.; Venkatesh, Gopi M.; Vishnupad, Krishna S.
PATENT ASSIGNEE(S): Eurand America, Inc., USA
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052848	A2	20010726	WO 2001-US1414	20010116 <--
WO 2001052848	A3	20011213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6451345	B1	20020917	US 2000-506051	20000217 <--
EP 1248616	A2	20021016	EP 2001-902073	20010116 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-177233P P 20000120
US 2000-506051 A 20000217
WO 2001-US1414 W 20010116

AB The present invention provides taste-masked microcapsules of Linezolid or the like (any member of the orally effective oxazolidinone or macrolide antibiotics), suitable for oral administration as a suspension, a fast-disintegrating, effervescent or chewable tablet, and more specifically relates to such oral dosage forms in which the bitter taste of Linezolid contained therein is masked by a combination of microencapsulation by solvent coacervation and subsequent functional membrane coating on said microcapsules. The taste-masked granules **thus** obtained release less than 5%, most preferably less than 3%, at a pH of 4.0 to 6.0 (pH of the saliva) but rapidly release (as a burst) at pHs of the upper intestinal tract. The taste-masked granules are optionally blended with other pharmaceutically acceptable excipients and filled into unit dose containers or compressed into fast-disintegrating/effervescent/chewable tablets. The contents of the Linezolid unit dose containers are suspended in an aqueous medium prior to oral administration to pediatric and geriatric patients, who are unwilling and/or find it difficult to swallow Linezolid tablets. In contrast, fast-disintegrating tablets on administration without water rapidly disperse into taste masked granules in the mouth. Linezolide granules containing Et cellulose were coated with Eudragit L30D for taste masking.

IT **165800-03-3**, Linezolid
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:488530 CAPLUS

DOCUMENT NUMBER: 135:92625

TITLE: Preparation of 5-acylaminomethyloxazolidin-2-ones as Factor Xa inhibitors.

INVENTOR(S): Straub, Alexander; Lampe, Thomas; Pohlmann, Jens; Roehrig, Susanne; Perzborn, Elisabeth; Schlemmer, Karl-Heinz

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 34 pp.
CODEN: GWXXBX
DOCUMENT TYPE: **Patent**
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19962924	A1	20010705	DE 1999-19962924	19991224 <--
WO 2001047919	A1	20010705	WO 2000-EP12492	20001211 <--
WO 2001047919	C2	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TR 200201636	T2	20021021	TR 2002-20020163	20001211 <--
BR 2000017050	A	20021105	BR 2000-17050	20001211 <--
EP 1261606	A1	20021204	EP 2000-993610	20001211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519141	T2	20030617	JP 2001-549389	20001211
EE 200200341	A	20031015	EE 2002-341	20001211
ZA 2002004188	A	20030527	ZA 2002-4188	20020527
BG 106825	A	20030228	BG 2002-106825	20020614
NO 2002003043	A	20020814	NO 2002-3043	20020621 <--
US 2003153610	A1	20030814	US 2002-181051	20020624 <--

PRIORITY APPLN. INFO.: DE 1999-19962924 A 19991224
WO 2000-EP12492 W 20001211

OTHER SOURCE(S): MARPAT 135:92625
GI



I

AB Title compds. [I; R1 = (substituted) thienyl, benzothienyl; R2 = organic residue; R3-R8 = H, alkyl; with exceptions], were prepared **Thus**, (5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholinophenyl)-1,3-oxazolidin-2-one, 5-chlorothiophene-2-carboxylic acid, hydroxybenzotriazole, EDCI, and diisopropylethylamine were stirred overnight in DMF to give 61.5% 5-chloro-N-[[(5S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-2-thiophenecarboxamide. 5-Chloro-N-[[(5S)-2-oxo-3-[4-(2-oxo-1-pyrrolidinyl)phenyl]-1,3-oxazolidin-5-yl]methyl]-2-thiophenecarboxamide

(preparation given) inhibited Factor Xa with IC50 = 4 nM.

IT **348626-07-3P 348626-08-4P 348626-09-5P**
348626-10-8P 348626-11-9P 348626-14-2P
348626-15-3P 348626-16-4P 348626-17-5P
348626-19-7P 348626-20-0P 348626-21-1P
348626-22-2P 348626-23-3P 348626-54-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-acylaminomethyloxazolidin-2-ones as Factor Xa inhibitors)

RN 348626-07-3 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-08-4 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-09-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-10-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-bromo-N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-11-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-14-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[3-fluoro-4-[4-(4-pyridinyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-15-3 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-16-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[[[(5-chloro-2-thienyl)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-17-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-19-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-2-oxo-3-[4-(1-piperidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-20-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-21-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-22-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-2-oxo-3-[4-(2-oxo-1-pyrrolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-23-3 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-2-oxo-3-[4-(1-pyrrolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-54-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-3-[3-fluoro-4-(4-oxido-4-

morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **168828-90-8 221201-36-1 268209-15-0**
348626-45-9 348626-47-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 5-acylaminomethyloxazolidin-2-ones as Factor Xa inhibitors)

RN 168828-90-8 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221201-36-1 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 268209-15-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 348626-45-9 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-[4-(4-pyridinyl)-1-piperazinyl]phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348626-47-1 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1-piperidinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **348626-50-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-acylaminomethyloxazolidin-2-ones as Factor Xa inhibitors)
RN 348626-50-6 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:482178 CAPLUS
DOCUMENT NUMBER: 135:76881
TITLE: Preparation of N-(oxooxazolidinylmethyl)thioamides and analogs as bactericides
INVENTOR(S): Hester, Jackson B., Jr.; Nidy, Eldon George; Perricone, Salvatore Charles; Poel, Toni-Jo
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: U.S., 93 pp., Cont.-in-part of U.S. 6,218,413.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 6255304	B1	20010703	US 1998-200904	19981127	<--
US 6218413	B1	20010417	US 1998-80751	19980518	<--
US 6362189	B1	20020326	US 2000-712055	20001114	<--
US 6342513	B1	20020129	US 2000-713739	20001115	<--
US 2001041728	A1	20011115	US 2001-822072	20010330	<--
US 6537986	B2	20030325			
US 2002016323	A1	20020207	US 2001-822666	20010330	<--

PRIORITY APPLN. INFO.: US 1997-48342P P 19970530
US 1998-80751 A2 19980518
US 1998-200904 A3 19981127
OTHER SOURCE(S): MARPAT 135:76881
GI



II

AB RZZ1CH2NHCSR1 [I; R = e.g., N-attached-(oxo)thiaazacycloalkyl; R1 = H, (alkyl)amino, alkyl, alkoxy, etc.; Z = e.g., fluorophenylene; Z1 = e.g., 2-oxooxazolidine-3,5-diyl] were prepared **Thus**, 1,4-hexahydrothiazepine was N-arylated by 3,4-F2C6H3NO2 and the reduced and N-protected product cyclocondensed with (R)-glycidyl butyrate to give, in 4 addnl. steps, title compound II. Data for biol. activity of I were

given.

IT 216868-57-4P 216868-61-0P 216868-64-3P
216868-65-4P 216868-66-5P 216868-67-6P
216868-68-7P 216868-69-8P 216868-70-1P
216868-71-2P 216868-72-3P 216868-73-4P
216868-74-5P 216868-75-6P 216868-76-7P
216868-77-8P 216868-78-9P 216868-79-0P
216868-80-3P 216868-81-4P 216868-82-5P
216868-84-7P 216868-85-8P 216868-86-9P
216868-87-0P 216868-88-1P 216868-90-5P
216868-92-7P 216868-95-0P 216868-96-1P
216868-99-4P 221202-51-3P 221202-52-4P
221202-63-7P 268208-12-4P 268208-13-5P
268208-14-6P 268208-16-8P 268208-67-9P
268208-69-1P 273376-65-1P 273376-66-2P
273376-67-3P 273376-68-4P 273376-69-5P
273376-70-8P 273376-71-9P 273376-72-0P
273376-73-1P 273376-74-2P 273376-75-3P
273376-77-5P 273376-78-6P 273376-79-7P
273376-80-0P 273376-81-1P 273376-82-2P
273376-83-3P 273376-84-4P 273376-85-5P
273376-86-6P 273376-87-7P 273376-88-8P
273376-89-9P 273376-90-2P 273376-91-3P
273376-92-4P 343869-89-6P 347361-61-9P
347361-62-0P 347361-63-1P 347361-64-2P
347361-65-3P 347361-66-4P 347361-67-5P
347361-68-6P 347361-69-7P 347361-70-0P
347361-71-1P 347361-72-2P 347361-73-3P
347361-74-4P 347361-75-5P 347361-76-6P
347361-77-7P 347361-78-8P 347361-79-9P
347361-80-2P 347361-81-3P 347361-82-4P
347361-83-5P 347361-84-6P 347361-85-7P
347361-86-8P 347361-87-9P 347361-88-0P
347361-89-1P 347361-90-4P 347361-91-5P
347361-92-6P 347361-93-7P 347361-94-8P
347361-95-9P 347361-96-0P 347361-97-1P
347361-98-2P 347361-99-3P 347362-00-9P
347362-01-0P 347362-02-1P 347362-03-2P
347362-04-3P 347362-05-4P 347362-06-5P
347362-07-6P 347362-08-7P 347362-09-8P
347362-10-1P 347362-11-2P 347362-12-3P
347362-13-4P 347362-14-5P 347362-15-6P
347362-16-7P 347362-17-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(oxooxazolidinylmethyl)thioamides and analogs as bactericides)

RN 216868-57-4 CAPLUS

CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-61-0 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(5-methyl-1,3,4-thiadiazol-2-yl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-64-3 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-65-4 CAPLUS
CN Thiourea, [[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216868-66-5 CAPLUS
CN Thiourea, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216868-67-6 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-68-7 CAPLUS
CN Thiourea, [[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-69-8 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-70-1 CAPLUS
CN Thiourea, [[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-71-2 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-72-3 CAPLUS
CN Thiourea, [[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-73-4 CAPLUS
CN Methanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-74-5 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-75-6 CAPLUS
CN Ethanethioamide, 2-chloro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-76-7 CAPLUS
CN Ethanethioamide, 2,2,2-trifluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-77-8 CAPLUS
CN Ethanethioamide, 2-fluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-78-9 CAPLUS
CN Ethanethioamide, 2,2-difluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-79-0 CAPLUS
CN Ethanethioamide, 2-cyano-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-80-3 CAPLUS
CN Ethanethioamide, 2,2-dichloro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-81-4 CAPLUS
CN Propanoic acid, 3-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]amino]-3-thioxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-82-5 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-84-7 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-85-8 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 216868-86-9 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-87-0 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-88-1 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3,5-difluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-90-5 CAPLUS
CN Thiourea, [[(5S)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-92-7 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-[[(aminothioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216868-95-0 CAPLUS
CN Thiourea, [[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-96-1 CAPLUS
CN Carbamodithioic acid, [[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216868-99-4 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221202-51-3 CAPLUS
CN Thiourea, N'-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221202-52-4 CAPLUS
CN Thiourea, N'-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221202-63-7 CAPLUS
CN Thiourea, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 268208-12-4 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 268208-13-5 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 268208-14-6 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 268208-16-8 CAPLUS
CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 268208-67-9 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 268208-69-1 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-65-1 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-66-2 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-67-3 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-68-4 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-69-5 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-70-8 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-71-9 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-72-0 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-73-1 CAPLUS
CN Thiourea, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-74-2 CAPLUS
CN Thiourea, N'-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-75-3 CAPLUS
CN 1-Azetidinecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-77-5 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-78-6 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10677451



RN 273376-79-7 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-80-0 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-81-1 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-82-2 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-83-3 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-84-4 CAPLUS

CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-formyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-85-5 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-formyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-86-6 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-formyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-87-7 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(4-formyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-88-8 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(tetrahydro-1-oxido-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-89-9 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-90-2 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(tetrahydro-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-91-3 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-92-4 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 343869-89-6 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 347361-61-9 CAPLUS
CN Ethanethioamide, N-[[(5S)-2-oxo-3-[4-(tetrahydro-1,4-thiazepin-4(5H)-yl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-62-0 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3,5-difluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-63-1 CAPLUS
CN Butanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-64-2 CAPLUS
CN Butanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-65-3 CAPLUS
CN Butanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-66-4 CAPLUS
CN Butanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-67-5 CAPLUS
CN Cyclobutanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-68-6 CAPLUS
CN Cyclopentanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-69-7 CAPLUS
CN Cyclohexanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-70-0 CAPLUS
CN Cyclopropaneethanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 347361-71-1 CAPLUS
CN Cyclobutaneethanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 347361-72-2 CAPLUS
CN Cyclopentaneethanethioamide, N-[[(5S)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-73-3 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-74-4 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-75-5 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-76-6 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10677451



RN 347361-77-7 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-78-8 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-79-9 CAPLUS
CN Propanethioamide, 2-methyl-N-[[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-80-2 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-81-3 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-82-4 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-83-5 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-84-6 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-85-7 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-86-8 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-87-9 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-88-0 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-89-1 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-90-4 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-91-5 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-92-6 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-93-7 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-94-8 CAPLUS
CN Butanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-95-9 CAPLUS
CN Butanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-96-0 CAPLUS
CN Butanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-97-1 CAPLUS
CN Butanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-98-2 CAPLUS
CN Cyclobutanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347361-99-3 CAPLUS
CN Cyclopentanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-00-9 CAPLUS
CN Cyclohexanecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-01-0 CAPLUS
CN Cyclopropaneethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-02-1 CAPLUS
CN Cyclobutaneethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-03-2 CAPLUS
CN Cyclopentaneethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-04-3 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-05-4 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-06-5 CAPLUS
CN Propanethioamide, N-[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-07-6 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-08-7 CAPLUS
CN Ethanethioamide, N-[[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-09-8 CAPLUS
CN Propanethioamide, N-[[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-10-1 CAPLUS
CN Propanethioamide, 2-methyl-N-[[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-11-2 CAPLUS
CN Cyclopropanecarbothioamide, N-[[(5S)-2-oxo-3-[4-(4-thiomorpholinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-12-3 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-13-4 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-14-5 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-15-6 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-16-7 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347362-17-8 CAPLUS
CN 1-Azetidinecarbothioamide, N-[[(5S)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **154590-54-2 165800-03-3 172966-53-9**
181996-80-5 195736-77-7 216869-24-8
216869-36-2 226991-66-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-(oxooxazolidinylmethyl)thioamides and analogs as bactericides)
RN 154590-54-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 165800-03-3 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 172966-53-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-oxo-1-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181996-80-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195736-77-7 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-[4-(5-methyl-1,3,4-thiadiazol-2-yl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-24-8 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-36-2 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226991-66-8 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **168828-65-7P 168828-67-9P 168828-90-8P**
198410-25-2P 216869-05-5P 216869-07-7P
216869-09-9P 216869-10-2P 216869-11-3P
216869-12-4P 216869-13-5P 216869-14-6P
216869-15-7P 216869-16-8P 216869-18-0P
216869-19-1P 216869-20-4P 216869-21-5P
216869-22-6P 216869-23-7P 216869-34-0P
216869-35-1P 216869-39-5P 216869-41-9P
216869-42-0P 216869-43-1P 216869-44-2P
216869-45-3P 216869-46-4P 216869-47-5P
216869-48-6P 216869-50-0P 273376-94-6P
273376-95-7P 273376-96-8P 273376-97-9P
273377-03-0P 273377-04-1P 273377-08-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(oxooxazolidinylmethyl)thioamides and analogs as bactericides)

RN 168828-65-7 CAPLUS
CN Formamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168828-67-9 CAPLUS
CN Acetamide, 2,2-dichloro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168828-90-8 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 198410-25-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-05-5 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-07-7 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216869-09-9 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216869-10-2 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-11-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-12-4 CAPLUS
CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216869-13-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216869-14-6 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-15-7 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216869-16-8 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-18-0 CAPLUS
CN Acetamide, 2-chloro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-19-1 CAPLUS
CN Acetamide, 2,2,2-trifluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-20-4 CAPLUS
CN Acetamide, 2-fluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-21-5 CAPLUS
CN Acetamide, 2,2-difluoro-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-22-6 CAPLUS
CN Acetamide, 2-cyano-N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-23-7 CAPLUS
CN Propanoic acid, 3-[[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-34-0 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-[(phenylmethoxy)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-35-1 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-(hydroxyacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-39-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216869-41-9 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216869-42-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-43-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2,6-difluoro-4-[(5S)-2-oxo-5-[[[(phenylmethoxy)carbonyl]amino]methyl]-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-44-2 CAPLUS
CN Carbamic acid, [[(5S)-3-[3,5-difluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-45-3 CAPLUS
CN Carbamic acid, [[(5S)-3-[3,5-difluoro-4-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-46-4 CAPLUS
CN Piperazine, 1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-4-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-47-5 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216869-48-6 CAPLUS
CN Piperazine, 1-[2-fluoro-4-[(5R)-5-(isothiocyanatomethyl)-2-oxo-3-oxazolidinyl]phenyl]-4-(hydroxyacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 216869-50-0 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-5-(isothiocyanatomethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 273376-94-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-95-7 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-96-8 CAPLUS
CN Carbamic acid, [[(5S)-3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273376-97-9 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273377-03-0 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(tetrahydro-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273377-04-1 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(tetrahydro-1-oxido-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273377-08-5 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-1,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:453092 CAPLUS
DOCUMENT NUMBER: 135:61555
TITLE: Preparation of lipopeptides as antibacterial agents
INVENTOR(S): Hill, Jason; Parr, Ian; Morytko, Michael; Siedlecki, Jim; Yu, Xiang Yang; Silverman, Jared; Keith, Dennis; Finn, John; Christensen, Dale; Lazarova, Tsvetelina; Watson, Alan D.; Zhang, Yan
PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA; et al.
SOURCE: PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044274	A1	20010621	WO 2000-US34205	20001215 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000016467	A	20020827	BR 2000-16467	20001215 <--
EP 1246838	A1	20021009	EP 2000-991867	20001215 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003517480	T2	20030527	JP 2001-544763	20001215
US 2004067878	A1	20040408	US 2000-737908	20001215 <--

NO 2002002887 A 20020812 NO 2002-2887 20020617 <--
PRIORITY APPLN. INFO.: US 1999-170946P P 19991215
US 2000-208222P P 20000530
WO 2000-US34205 W 20001215
OTHER SOURCE(S): MARPAT 135:61555
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Lipopeptides I [R is -N(B)(X)n-A; B is X''RY, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; RY is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl; X, X'' are C:O, C:S, C:NH, C:NRX, S:O or SO2; n is 0 or 1; RX is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy; A is H, NH2, NHRA, NRARB, heteroaryl, cycloalkyl, heterocyclyl (RA, RB are alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy) or when n is 0, then A is P(O)(OR50)OR51, P(O)R52R53, or P(O)(OR50)R53, where R50-R53 are alkyl; alternatively B and A may form a 5-7 membered heterocyclic or heteroaryl ring; R1 is defined similarly to R (with provisos); R2 is CH2CR17R18-ring, where R17 and R18 are hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl, etc. or CR17R18 are CO, C(:S), oxime or hydrazone group] were prepared for use as antibacterials. **Thus**, treating daptomycin with 4-fluorobenzaldehyde and sodium triacetoxyborohydride in dry DMF for 24 h afforded I [R = NHCO(CH2)8Me, R1 = NHCH2C6H4F-4, R2 = CH2COC6H4NH2-o], which showed MIC (S. Aureus) ≤ 1 μg/mL.

IT **165800-03-3**, Linezolid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of lipopeptides as antibacterial agents)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:453090 CAPLUS
DOCUMENT NUMBER: 135:61554
TITLE: Preparation of novel lipopeptides as antibacterial agents
INVENTOR(S): Hill, Jason; Parr, Ian; Morytko, Michael; Siedlecki, Jim; Yu, Xiang Yang; Silverman, Jared; Keith, Dennis; Finn, John; Christensen, Dale; Lazarova, Tsvetelina; Watson, Alan D.; Zhang, Yan
PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044272	A2	20010621	WO 2000-US34118	20001215 <--
WO 2001044272	A3	20011129		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002025924	A1	20020228	US 2000-738742	20001215 <--
EP 1240181	A2	20020918	EP 2000-986444	20001215 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000017026	A	20030107	BR 2000-17026	20001215
JP 2003517004	T2	20030520	JP 2001-544761	20001215
NO 2002002888	A	20020802	NO 2002-2888	20020617 <--

PRIORITY APPLN. INFO.: US 1999-170943P P 19991215
WO 2000-US34118 W 20001215

OTHER SOURCE(S): MARPAT 135:61554
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Lipopeptides I [R is -N(B)(X)n-A; B is X''RY, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; RY is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl; X, X'' are C:O, C:S, C:NH, C:NRX, S:O or SO2; n is 0 or 1; RX is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy; A is H, NH2, NHRA, NRARB, heteroaryl, cycloalkyl, heterocyclyl (RA, RB are alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy) or when n is 0, then A is P(O)(OR50)OR51, P(O)R52R53, or P(O)(OR50)R53, where R50-R53 are alkyl (with provisos); R1 is defined similarly to R; R2 is CH2CR17R18-ring, where R17 and R18 are hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl, etc. or CR17R18 are CO, C(:S), oxime or hydrazone

group] were prepared for use as antibacterials. **Thus**, daptomycin was Boc-protected, deacylated using deacylase enzyme, and reacted with octyl isocyanate to give I [R = NHCONH(CH2)7Me, R1 = NH2, R2 = CH2COC6H4NH2-o], which showed MIC (S. Aureus) > 1 ≤ 10 μg/mL mg/kg.

IT **165800-03-3**, Linezolid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of novel lipopeptides as antibacterial agents)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:453089 CAPLUS
DOCUMENT NUMBER: 135:61553
TITLE: Preparation of novel lipopeptides as antibacterial agents
INVENTOR(S): Hill, Jason; Parr, Ian; Morytko, Michael; Siedlecki, Jim; Yu, Xiang Yang; Silverman, Jared; Keith, Dennis; Finn, John; Christensen, Dale; Lazarova, Tsvetelina; Watson, Alan D.; Zhang, Yan
PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044271	A2	20010621	WO 2000-US34051	20001215 <--
WO 2001044271	A3	20020307		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,

YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2002058785 A1 20020516 US 2000-739535 20001215 <--
EP 1240182 A2 20020918 EP 2000-991409 20001215 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2000017028 A 20030107 BR 2000-17028 20001215
JP 2003517003 T2 20030520 JP 2001-544760 20001215
NO 2002002886 A 20020802 NO 2002-2886 20020617 <--
PRIORITY APPLN. INFO.: US 1999-170945P P 19991215
WO 2000-US34051 W 20001215
OTHER SOURCE(S): MARPAT 135:61553
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Lipopeptides I [R and R1 are -N(B)(X)n-A; B is X'RY, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; RY is hydrido, alkyl, alkenyl, alkynyl, aryl,heteroaryl, cycloalkyl, heterocyclyl or hydroxyl; X, X' are C:O, C:S, C:NH, C:NRX, S:O or SO2; n is 0 or 1; RX is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy; A is H, NH2, NHRA, NRARB, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl (RA, RB are alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy) or when n is 0, then A is P(O)(OR50)OR51, P(O)R52R53, or P(O)(OR50)R53, where R50-R53 are alkyl; alternatively, B and A together form a 5-7 membered heterocyclic or heteroaryl ring; R2 is CH2CR17R18-ring, where R17 and R18 are hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl, etc. or CR17R18 are CO, C(:S), oxime or hydrazone group] were prepared for use as antibacterials. **Thus**, sulfamic acid (89.9 mg) and sodium nitrite (51.1 mg) were added to a solution of daptomycin (1 g) in 0.1 M HCl (31 mL) at 0°. Aqueous potassium O-ethylxanthic acid (497 mg) was added and the mixture was heated at 60° for 1 h to afford I [R = NHCO(CH2)8Me, R1 = NH2, R2 = CH2CO-o-C6H4SC(S)OEt], which showed MIC (S. Aureus and E. faecalis) and ED50 > 1 ≤ 10 μg/mL or mg/kg, resp.

IT **165800-03-3**, Linezolid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of novel lipopeptides as antibacterial agents)

RN 165800-03-3 CAPLUS

CN Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L12 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:453039 CAPLUS
DOCUMENT NUMBER: 135:46171
TITLE: Preparation of N-[[[(benzoyloxyacetyl)piperazino]phenyl]oxazolidinylmethyl]alkanthioamides and analogs as bactericides
INVENTOR(S): Hester, Jackson B., Jr.
PATENT ASSIGNEE(S): Pharmacia + Upjohn Company, USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001044212	A1	20010621	WO 2000-US32432	20001206	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2001018058	A5	20010625	AU 2001-18058	20001206	<--
US 6281210	B1	20010828	US 2000-732088	20001206	<--
BR 2000015177	A	20020618	BR 2000-15177	20001206	<--
EP 1242395	A1	20020925	EP 2000-980849	20001206	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003516977	T2	20030520	JP 2001-544702	20001206	
ZA 2002002953	A	20030715	ZA 2002-2953	20020415	
NO 2002002811	A	20020613	NO 2002-2811	20020613	<--

PRIORITY APPLN. INFO.: US 1999-170675P P 19991214
WO 2000-US32432 W 20001206
OTHER SOURCE(S): MARPAT 135:46171

AB R4Z4CO2CH2COZ1Z2Z3CH2R [I; R = NHC(:X)R1 or ZR9; R1 = H, (alkyl)amino, alkyl, alkoxy, etc.; R4 = NR5COCHR6NR7R8 or CHR5NR7R8; R5 = H or Me; R6 = H or (un)substituted alkyl; R7,R8 = H or alkyl; NR7R8 = heterocyclyl; R9 = heterocyclyl; Z = O, S, NH; Z1 = piperazine-1,4-diyl throughout; Z2 = 2,6-(un)substituted-1,4-phenylene; Z3 = e.g., 2-oxo-3,5-oxazolidinediyl; Z4 = 1,3- or 1,4-phenylene] were prepared for use against gram neg. bacteria. **Thus**, (S)-R10Z1Z2Z3CH2NHR11 (II; Z2 = 2-fluoro-1,4-phenylene, Z3 = 2-oxo-3,5-oxazolidinediyl)(III; R10 = H, R11 = Boc) was amidated by PhCH2OCH2COCl and the debenzylated product esterified by 4-(ClH2C)C6H4COCl to give, after amination and deprotection, III [R10 = 4-(Me2NH2C)C6H4CO2CH2CO](IV; R11 = H). The latter was amidated by EtCS2Me to give IV (R11 = CSEt). Data for biol. activity of I were given.

IT **345224-04-6P 345224-05-7P 345224-06-8P**
345224-07-9P 345224-08-0P 345224-09-1P
345224-10-4P 345224-12-6P 345224-13-7P
345224-14-8P 345224-15-9P 345224-16-0P
345224-17-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[[[(benzoyloxyacetyl)piperazino]phenyl]oxazolidinylmethyl] alkanthioamides and analogs as bactericides)

RN 345224-04-6 CAPLUS

CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

S

RN 345224-05-7 CAPLUS
CN Benzoic acid, 3-[(dimethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

S

RN 345224-06-8 CAPLUS
CN Benzoic acid, 3-(4-morpholinylmethyl)-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-07-9 CAPLUS
CN Benzoic acid, 3-[(4-methyl-1-piperazinyl)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-08-0 CAPLUS
CN Benzoic acid, 3-[(diethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-09-1 CAPLUS
CN Benzoic acid, 4-[(diethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-10-4 CAPLUS
CN Benzoic acid, 4-(4-morpholinylmethyl)-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-12-6 CAPLUS
CN Benzoic acid, 4-[(4-methyl-1-piperazinyl)methyl]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-13-7 CAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-[[(cyclopropylthioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-14-8 CAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-[[(aminothioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-15-9 CAPLUS
CN Benzoic acid, 4-[(aminoacetyl)amino]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-16-0 CAPLUS
CN Benzoic acid, 4-[(aminoacetyl)amino]-, 2-[4-[4-[(5S)-5-[[(cyclopropylthioxomethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-17-1 CAPLUS
CN Benzoic acid, 4-[[(2S)-2-amino-1-oxopropyl]amino]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

IT **273376-95-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[[[(benzoyloxyacetyl)piperazino]phenyl]oxazolidinylmethyl] alkanthioamides and analogs as bactericides)
RN 273376-95-7 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **345224-18-2P 345224-19-3P 345224-20-6P**
345224-21-7P 345224-22-8P 345224-23-9P
345224-24-0P 345224-25-1P 345224-26-2P
345224-27-3P 345224-28-4P 345224-29-5P
345224-30-8P 345224-31-9P 345224-32-0P
345224-33-1P 345224-34-2P 345224-35-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[[[(benzoyloxyacetyl)piperazino]phenyl]oxazolidinylmethyl] alkanthioamides and analogs as bactericides)

RN 345224-18-2 CAPLUS

CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345224-19-3 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345224-20-6 CAPLUS
CN Benzoic acid, 4-(chloromethyl)-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-21-7 CAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-22-8 CAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345224-23-9 CAPLUS
CN Benzoic acid, 3-(chloromethyl)-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-24-0 CAPLUS
CN Benzoic acid, 3-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-25-1 CAPLUS
CN Benzoic acid, 3-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345224-26-2 CAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345224-27-3 CAPLUS
CN Benzoic acid, 4-[(dimethylamino)methyl]-, 2-[4-[2-fluoro-4-[(5R)-5-(isothiocyanatomethyl)-2-oxo-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345224-28-4 CAPLUS
CN Carbamic acid, [[(5S)-3-[3-fluoro-4-[4-[[(4-nitrobenzoyl)oxy]acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

O

RN 345224-29-5 CAPLUS
CN Carbamic acid, [[(5S)-3-[4-[[(4-aminobenzoyl)oxy]acetyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

O

RN 345224-30-8 CAPLUS
CN Benzoic acid, 4-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 345224-31-9 CAPLUS
CN Benzoic acid, 4-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

● HCl

PAGE 2-B



RN 345224-32-0 CAPLUS
CN Benzoic acid, 4-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 345224-33-1 CAPLUS
CN Benzoic acid, 4-[[(2S)-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]amino]-, 2-[4-[4-[(5S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 345224-34-2 CAPLUS
CN Benzoic acid, 4-[[(2S)-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]amino]-, 2-[4-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● HCl

RN 345224-35-3 CAPLUS
CN Benzoic acid, 4-[[(2S)-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]amino]-, 2-[4-[2-fluoro-4-[(5S)-2-oxo-5-[[(1-thioxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	86.00	399.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.09	-11.09

STN INTERNATIONAL LOGOFF AT 10:52:42 ON 15 JUN 2004